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A c c e p t e d M a n u s c r i p t
Background: 26 27
Carcinoma of the cervix is a significant cause of mortality in women, accounting for around 28 275,000 deaths worldwide annually (1) . Mortality rates have significantly reduced over time in 29 developed countries due to successful cervical screening programs using the Papanicolaou (2) 30 test, aimed at early detection of cytological abnormalities (3) . 31
32
Infection with an oncogenic or high-risk (2) human papillomavirus (HPV) genotype is the major 33 causative factor for development of precancerous high-grade cervical intraepithelial lesions 34 (CIN2/3) and ultimately cervical cancer (4-7) (8) . However, the majority of cervical HPV infections 35 are transient, asymptomatic and cleared by host immunity. There are approximately 40 known 36 genotypes that specifically target the anogenital mucosa which are divided into low-risk (LR) 37 and high-risk (2) types, through epidemiological association with anogenital cancers (9, 10) . 38
Virtually all cases of cervical cancer and/or high-grade CIN2/3 are preceded by persistent HR-39
HPV infection(s). 40 41
Currently, there are two licensed prophylactic HPV vaccines; a bivalent HPV 16/18 (Cervarix 42 TM ) vaccine and a quadrivalent HPV 6/11/16/18 (Gardasil ® ) one (11) . Both vaccines prevent 43 infection with the two major oncogenic types causing 70% of cancers of the cervix, while the 44 quadrivalent vaccine also targets HPV types causing over 90% of genital wart cases. In 45 Australia, the quadrivalent HPV vaccine was approved for use in 2006, with free vaccination 46 being made available for school-aged girls from April 2007 through the national HPVvaccination program (12-18 years-old) (12) . Between July 2007 and December 2009 the vaccineM a n u s c r i p t 4 was also offered free to all women under the age of 27 years through community vaccination 49 providers. The free school-based program for 12 to 13-year-old girls is ongoing, with adolescent 50 males being added from February 2013. 51
52
Prior to HPV vaccination in Australia, information on HPV type-specific prevalence across the 53 general population was limited. Most HPV genotyping studies in Australia focused on the 54 analysis of biopsies/liquid-based samples from patients with CIN2/3 and/or cervical cancer (13) (14) (15) (16) (17) . 55
From these studies, HPV 16 and 18 were identified as the most common genotypes among 56 women with higher grade disease, in line with international findings. However, very little is 57 known about the prevalence of other HPV genotypes. To address, a nationwide study of HPV 58 prevalence in sexually active Australian women presenting for Pap testing at 34 sites across the 59 country was established: the Women Human papillomavirus Indigenous Non-indigenous Urban 60
Rural Study (WHINURS) (18) . The aim of WHINURS was to ascertain HPV genotype prevalence 61 rates among Australian women presenting for routine Pap smears across Australia, prior to 62 rollout of the HPV prophylactic vaccines. Population based estimates adjusted for risk factors for 63 women up to age 40 have been presented elsewhere and address the primary research questions 64 regarding possible differences between Indigenous and remote dwelling women compared to 65 other Australian women (18) . 66 M a n u s c r i p t 5
Objectives 68
To provide more comprehensive data on the age-related distribution of HPV genotypes in 69
Australian women prior to vaccination by including women up to age 60, and to determine the 70 association between genotypes and cytological changes on Pap smears. 71
Participants were recruited between April 2005 and February 2008 from all Australian 76 jurisdictions, with deliberate over-sampling of specimens from more remote locations and from 77 Indigenous women (18) . (19, 20) and 88 tested as described previously (18) . Briefly, 10μl of DNA was screened by HPV AMPLICOR 89 (AMP) for the detection of 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) ; with this result 90 used for clinical reporting. All extracts negative for HR-HPV by AMP were also analyzed by an 91 "in-house" PGMY09/11-based HPV consensus PCR/ELISA (20μl of DNA) detecting mucosal 92 HPV types, as previously described (21) (Table 2) . For women with a LGA Pap result, younger women hadM a n u s c r i p t 11 a significantly higher prevalence of multiple types (p<0.001), HR types (p=0.002) and vaccine-179 preventable types (6/11/16/18) (p=0.003). 180
181
For women with a HGA Pap result, all except one had one or more HPV genotypes detected. 182
Within our limited sample size no difference in the prevalence of most individual HPV 183 genotypes were noted between the age groups, although younger women had higher prevalence 184 of a vaccine-preventable genotype (p=0.02) and were more likely to have only a vaccine 185 preventable type detected (p=0.003). 186
Discussion 189
This is the largest group of cervical specimens collected from sexually active Australian women 190 prior to vaccination for HPV genotyping . We found a high rate of HPV detection (39%) and 191 large diversity of types present. Use of highly sensitive and multiple assay types allowed us to be 192 confident in the detection and identification of these types. International meta-analyses of data 193 from a range of other countries have shown that detection of HPV is highly correlated with 194 younger age (24, 25) . Importantly our data add an Australian contribution to the international 195 knowledge about HPV types detected in abnormal Pap tests prior to introduction of the vaccine, 196 data that has been conspicuously absent until now (26, 27) . Among women in our sample with a 197 low-grade abnormality detected on cytology, one third had a vaccine preventable type detected, 198 but it is noteworthy that 95% of these LGAs also had a non-vaccine type detected. Half of the 199 women with a high grade abnormality on cytology had HPV16 detected, in line with emerging 200 international evidence (28, 29) showing the enrichment of the more virulent HPV 16 causing high-201 grade lesions faster. In general, younger women were much more likely to have vaccine 202 preventable types detected and only a vaccine preventable type as a single type detected than 203 older women. We did not find any significant differences in vaccine preventable HPV prevalence 204 between Indigenous and non-Indigenous women with cytological abnormalities, although the 205 study was relatively underpowered to do so. Our findings that HPV56 was more common in low 206 grade lesions and that HPV66 was more common in high grade lesions from Non-Indigenous 207 women need to be interpreted with caution due to multiple comparisons, the relatively small 208 sample size and weak statistical association (p=0.03). 209
13
The high prevalence of HPV detected in this group of specimens probably reflects a combination 211 of the population tested and the high sensitivity of the methods for HPV detection used (19) . Our 212 population included a large number of young women, including teenagers, who have very high 213 rates of HPV infection; did not exclude women with previous or current Pap abnormalities 214 amongst whom HPV infection is more frequent; and enrolled women attending clinics whose 215 services are free, which may increase the proportion of women of lower socioeconomic status, a 216 risk factor for under screening and cervical cancer (30) . 217 218 In addition to the study population criteria, the method of HPV detection is crucial when 219 comparing inter-laboratory HPV genotype prevalence studies, particularly due to the extensive 220 variation in available tests. The HPV-LA genotyping test used in this study uses 5 times more 221 DNA than the AMP assay, which would be expected to increase the detection rate. Moreover, 222 LA detects 37 HPV types compared with 13 for the AMP (19) . Recent studies that have used the 223 LA test on screening populations have shown similar HR-HPV rates of 22% among Italian 224 women (31) , mean age 34y; and 30% among Greek women (2) , mean age 28.4y. 225
226
The prevalence of any HPV in the current study declined with age, as did the prevalence of HR, 227 multiple and vaccine-preventable HPV types. Women ≤ 25 years had the highest levels of HPV 228 infections. In this group, HPV 16 and/or 18 were common at 21% combined (17% and 7%, 229 individually), while HPV 6 and/or 11 were detected in 6% (5% and 1% respectively). In all, 230 vaccine preventable types were identified in 25% of women ≤ 25 years. Vaccination has already 231 been shown to have a significant impact on HPV infection in this age group, with Australian data 232
showing a decrease in prevalence of vaccine preventable HPV types by 77% among women agedA c c e p t e d M a n u s c r i p t 14 18-24 years post vaccination (32) . Vaccine-only types were detected in 5% of these women. The 234 prevalence of single, HR HPV-only, and HPV 16/18 all demonstrated a significant increase with 235 cytologically predicted disease in line with other reports. HR-HPV increased from 21% among 236 cytology-normal women to 81% in women with HGA, consistent with consensus findings that 237 such types are the causative agent of cervical cancer (7) (8) . The five most common genotypes 238 among women with HGA cytology were all HR-types, being HPV 16 (51%), 18 (15%), 52 239 (13%), 31 (11%), and 33 (11%). Interestingly, there were five cases whereby LR HPV types 240 were exclusively detected among women with HGA Pap cytology prediction. Two of these 241 women had a single HPV 69 infection, which has an undetermined risk association (belonging to 242 the same group as HPV 51). However, without histological findings, a definitive diagnosis 243 (rather than a predictive one provided by Pap smear) of these cases could not be made. 244
245
Although new data is beginning to emerge internationally (33) , the data reported in this study 246 provide a valuable insight into the HPV genotype distribution among women participating in 247 cervical screening within the Australian population, prior to the implementation of the current 248 HPV vaccines. This information provides important baseline data for assessing HPV vaccine 249 impact on HPV infection rates and type distribution in Australia, which has achieved the most 250 broadly targeted, high coverage HPV vaccine program using quadrivalent HPV vaccine to date 251 (12) . Dramatic declines in vaccine preventable HPV types have already been recorded, using the 252 data presented in detail here (32) .
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M a n u s c r i p t Figure 1A : Age-stratified HPV cervical prevalence according to risk association* in 2620
Australian women attending Pap testing High risk defined as positive for 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 . Possible high risk defined as positive for types 26,53,66,73 or 82. All other types designated low risk. 
